<DOC>
	<DOC>NCT01615419</DOC>
	<brief_summary>This multi-center, observational study will evaluate the use in clinical practice and efficacy of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the approved label will be followed for 6 months.</brief_summary>
	<brief_title>An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Moderate to severe rheumatoid arthritis , according to the revised ACR criteria Patients initiated on RoActemra/Actemra treatment (in accordance with the local label) on their treating physicians decision RoActemra/Actemra treatment more than 8 weeks prior to enrolment visit Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use Treatment with any investigational agent within 4 weeks (or 5 halflives of investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra History of autoimmune disease or of any joint inflammatory disease other than RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>